KYV-101, an autologous fully-human anti-CD19 CAR T-cell immunotherapy
CCM-RNT-202402
Phase 2 small_molecule active
Quick answer
KYV-101, an autologous fully-human anti-CD19 CAR T-cell immunotherapy for ANCA-IgG-positive ANCA Associated Vasculitis is a Phase 2 program (small_molecule) at Kyverna Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Kyverna Therapeutics
- Indication
- ANCA-IgG-positive ANCA Associated Vasculitis
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active